GoggleDocs
@GoggleDocs
Followers
4K
Following
4K
Media
733
Statuses
3K
🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube https://t.co/VSFSwEDXDD |Educate, Motivate, Activate!
London, England
Joined October 2020
Retatrutide TRIUMPH-4: 29% weight loss at 12mg. Impressive. ⚠️But here’s what needs discussing: 20.9% experienced dysesthesia (abnormal skin sensations) at that dose vs 0.7% placebo. Before everyone panics: - Generally mild - Rarely led to discontinuation - Overall dropout
0
3
3
Thank you @Damian_Roland for this comment regards my query on primary care and viral infections/ checking glucose feasibility for diagnosis of #T1Diabetes My view- FWIW? 1. The non-shifting of data around DKA at diagnosis for #T1D via @NPDA_RCPCH would suggest standard
@parthaskar @kamleshkhunti @DrSdeG @GoggleDocs @AbbieSBrooks @drgandalf52 @MFAminGP @BenAllenGP @scelee1 @DSNforumUK @WeNurses @DrSelvarajah @pcdosociety I can’t believe that this wouldn’t have significant unintended consequences especially given the volumes of Children involved. But I believe in evidence based rather than emotion based policy. Get @NIHRresearch to do a commissioned call & I’d happy to submit to run the study…
2
5
18
If a child presents to primary care with non specific symptoms / potential viral… Would doing a finger prick glucose test add too much to present workload? To pick up #T1Diabetes? A question for my primary care colleagues please 🙏🏽 @kamleshkhunti @DrSdeG
40
8
53
📊 Young-Onset Hypertension in Type 2 Diabetes 🕑 Young-onset HTN (YOH): <45 years Compared with matched T2D controls- ⬆️ risk of ❤️ Cardiovascular Disease 🧠 Heart Failure 🗂️ Chronic Kidney Disease ⚰️ All-Cause Death ♀️ Women affected more → greater excess risk for CVD &
2
12
35
#GLP1's & erectile function: friend or foe? 🔬 New Biomolecules review: mostly friend❗️ ✅ Improve endothelial function ✅ Boost testosterone via weight loss ✅ REWIND: dulaglutide cut ED risk (HR 0.92) Responses vary - ask at follow-up. 🔗 https://t.co/JHuRu3OrYE
0
6
36
📊✨ GLP-1RA Exposure & Pregnancy Outcomes 🚫 GLP-1RAs are contraindicated in pregnancy, but many discontinue them just before or early in gestation. Large cohort study (149,790 pregnancies) examined how that affects gestational weight gain & pregnancy outcomes. 📌 Key
3
10
53
🔥Metformin & #SGLT2i for almost all in draft @NICEComms #t2d guidance! ⚠️But no drug is without harm & we must balance the benefits against possible adverse effects 💡Have a look at my @YouTube videos for people living with #T2D considering #sglt2is
https://t.co/Lrz1EBiMtE
0
16
44
❗️No superiority for oral semaglutide in Alzheimers disease❗️ No surprises from my side despite the hyperbole in social media - population,intervention&duration may have impacted, also other measures required. Nevertheless - excellent to see a trial in this area @kamleshkhunti
0
2
9
🧠People with #T2DM face ↑ risk of cognitive decline. ✨ Systematic review of 18 RCTs 💡 Early & sustained GLP-1RA therapy may protect the brain! https://t.co/wMvrOvgkdc
1
9
32
#GLP1 is forcing Big Food to finally reform. Not through regulation, but ⤵️💰 12% of US adults on GLP-1s = ⤵️8.6% in household food spending. 🔹Ultra-processed foods hit hardest 🔸 $12bn potential loss for junk food. Nestlé, General Mills, even Greggs scrambling to
8
22
83
Excellent few days speaking at #NEDSCON in Guwahati, Assam - appreciate the invite and the topics discussed - exploring frailty, sarcopenia & dementia in the age of incretin therapies & beyond! #DIADEM
@GoggleDocs @kamleshkhunti @banshisaboo @EASDnews @DrRonaldMa1 @TBattelino
3
2
14
🍸 GLP-1 drugs may curb alcohol use risk Target trial emulation in people with T2 diabetes Significantly lower risk of developing alcohol use disorder vs DPP-4 inhibitors Potential of incretin-based therapies beyond weight and glycaemic control. #GLP1 #Tirzepatide
7
16
75
*NEWS* The release of the latest #T1D comic book - on the occasion of #WorldDiabetesDay Where the topics are around prediction of #T1Diabetes; antibodies and future exciting world of immunotherapy . In addition, the last few years have seen a huge rise in the number of people
2
15
50
GLP-1s Vs DPP-4s & Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study People looking at cognitive impairment more and more …. Just in different subgroups… are haemodoalysis patients the ideal target group 🤔 #DIADEM
https://t.co/4yoJTJ0KZ2
0
1
5
My last “magic trick” for the world of #T1Diabetes in england 🏴 was to negotiate & secure funding for #ClosedLoops for Year 3, 4 and 5 If the news I am hearing is correct? I swear I will re-enact this gif #gbdoc 💙
1
10
69
A great day yesterday continuing the education to the VIPs - those with diabetes. Thank you @Sheffield_DUK @DiabetesUK for the invite. @GoggleDocs @kamleshkhunti
0
3
16
❗️A trial we have kept an eye on announces primary outcome met ❗️ FINE-ONE Finerenone in T1DM potentially provides an opportunity to address renal risk (maybe more) in this population with unmet need https://t.co/1Hb6fsg5Dh
@AmarPut @drpatrickholmes @kamleshkhunti
2
25
59
How poignant @triggersbroom17 🥹 In honour of Lyla? @NHSDiabetesProg will work to raise awareness #T1D on World Diabetes Day, Fri 14 Nov. The day is an opportunity to raise issues around spotting & diagnosing T1D in young children & adults The least we can do 💙 #gbdoc
Unbelievable. So bittersweet This is for you, Lyla, and the Type 1 Diabetes Community, diagnosed and undiagnosed. #LylasLaw #diabetes #thankyouforyoursupport #proud #fyp
2
24
60
🌍 Type 2 diabetes is rising worldwide-but unevenly. Prevalence is highest in the Middle East & North Africa, and lowest in parts of Europe & sub-Saharan Africa. Urbanisation, obesity, processed diets, and reduced activity drive this surge -especially in rapidly developing
0
7
25